<DOC>
	<DOCNO>NCT02940132</DOCNO>
	<brief_summary>SC10914 potent selective PARP-1 PARP-2 inhibitor . This study aim determine safety , tolerability , pharmacokinetic/pharmacodynamics profile increase dos SC10914 administer orally patient advance solid tumor . Furthermore , safety efficacy SC10914 patient advance solid tumor negative expression ATM BRCA1 BRCA2 mutation evaluate expanded cohort establish Recommended Phase 2 Dose ( RP2D ) .</brief_summary>
	<brief_title>A Study SC10914 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Signed write informed consent Aged 1870 year Dose escalation study : Subjects diagnose advanced solid malignancy refractory standard therapy standard therapy exists/Dose Expansion study : Subjects diagnose advanced solid malignancy refractory standard therapy standard therapy exists negative expression ATM BRCA1 BRCA2 mutation Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Have measurable lesion exists ( RECIST 1.1 ) Life expectancy≥3 month Have adequate bone marrow , hepatic renal function Allergic constitution hypersensitivity investigational drug relevant drug Patients receive previous treatment PARP inhibitor Patients accept anticancer therapy include chemotherapy , radiotherapy , endocrinotherapy , immunotherapy , Chinese herbal treatment investigational drug within 4 week prior trial entry ( long period depend define characteristic drug use eg , . 6 week mitomycin C nitrosourea ) With serious preexist medical condition , significant cardiovascular disease psychogenic disorder With family history long QT syndrome QTc ≥ 450 m With persistent CTCAE ≧grade 2 toxicity ( exclude alopecia ) cause prior medication With symptomatic brain metastasis Pregnancy lactation With Hepatitis B C human immunodeficiency virus infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>